News from bioinvent A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages

Latest

08 Nov, 2019, 07:35 GMT BioInvent to Present BI-1206 Preclinical Data in Mantle Cell lymphoma at ASH 2019

BioInvent International AB (publ) (OMXS: BINV) today announces it will make a poster presentation with preclinical data on BI-1206 at the annual...


23 Oct, 2019, 12:48 BST BioInvent Signs Manufacturing Agreement With Cancer Research UK Expected to Generate Approximately SEK 30 Million (~$3 Million)

BioInvent International AB (publ) (OMXS: BINV) today announces it has concluded a production agreement with Cancer Research UK, the world's largest...


22 Aug, 2019, 07:47 BST BioInvent: Interim Report January 1 - June 30, 2019

"We are executing according to plan. Our lead candidate BI-1206 has shown encouraging initial data in hematological cancers, and has now also entered ...


21 Aug, 2019, 08:19 BST BioInvent Will Conduct Phase l/lla Trial With BI-1206 in Combination With Pembrolizumab (Keytruda) in Solid Tumors

BioInvent International AB (publ) (OMXS: BINV), a company focused on the discovery and development of novel and first-in-class immuno-modulatory...


20 Aug, 2019, 09:54 BST BioInvent's Partner Oxurion NV has Reported Topline Month 3 Results of Phase lla Study Evaluating THR-317 (anti-PLGF), in Combination With Ranibizumab, for DME

BioInvent International AB's (publ) (OMXS: BINV) partner Oxurion NV has today reported topline data from a Phase lla study evaluating THR-317, a...


15 Aug, 2019, 11:36 BST USPTO Intends to Grant BioInvent Patent Relating to BI-1206

BioInvent International AB (OMXS: BINV) today announces that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance...


14 Aug, 2019, 11:45 BST Invitation to Presentation of BioInvent's Interim Report Q2-2019 on August 22, 2019

BioInvent International AB (OMXS: BINV) will issue its interim report for the second quarter 2019 on Thursday August 22 at 8.30 a.m. CEST, followed...


31 Jul, 2019, 12:10 BST BioInvent Announces Selection of First Target Discovered by BioInvent's Proprietary F.I.R.S.TTM Technology Platform Under Collaboration With Pfizer Inc.

BioInvent International AB ("BioInvent" or the "Company") (OMXS: BINV) today announces that Pfizer Inc. ("Pfizer") (NYSE: PFE) has selected the first ...


04 Jul, 2019, 12:08 BST BioInvent Receives Milestone Payment Related to TAK-169 Investigational New Drug Application

BioInvent International AB (BINV) today announced it will receive a $0.5 million milestone payment related to the acceptance by the U.S. Food and...


02 Jul, 2019, 08:12 BST Bioinvent Receives Ind Approval For Phase I/iia Trial of Anti-fcγriib Antibody

BioInvent International AB (BINV) today announces it has received authorization from the U.S. Food and Drug Administration (FDA) to proceed with an...


12 Jun, 2019, 11:08 BST BioInvent Publishes First Clinical Data From BI-1206 Phase l/lla Trials

BioInvent International AB (BINV) today announces the publication of the first data from two parallel Phase l/lla clinical trials of its lead product ...


03 Jun, 2019, 07:56 BST BioInvent Submits IND for Phase I/IIa Trial of Anti-FcγRIIB Antibody

BioInvent International AB (OMXS: BINV) today announces the submission to the U.S. Food and Drug Administration (FDA) of an Investigational New Drug...


22 May, 2019, 07:45 BST BioInvent Interim Report January 1 - March 31, 2019

Net sales SEK 17.4 (11.3) million Earnings after tax SEK -27.8 (-24.9) million Earnings after tax per share before and after dilution: SEK -0.08...


26 Apr, 2019, 07:58 BST BioInvent Receives €0.75 Million Milestone Under Mitsubishi Tanabe Pharma Partnership

BioInvent International AB (OMXS: BINV) announced today that it has received a €0.75 million milestone payment under its collaboration with...


26 Mar, 2019, 08:02 GMT BioInvent and Transgene Extend Their Collaboration to Develop Multifunctional Oncolytic Viruses for the Treatment of Solid Tumors

BioInvent International AB (OMXS: BINV), a biotech company focused on the discovery and development of novel immuno-regulatory antibodies to treat...


21 Mar, 2019, 09:25 GMT BioInvent Unveils Broad Anti-TNFR2 Program to Treat Solid Tumors

ioInvent International AB (OMXS: BINV), focused on the discovery and development of novel and first-in-class immuno-regulatory antibody-based...


19 Mar, 2019, 10:08 GMT Notice to Annual General Meeting in BioInvent International AB

The shareholders of BioInvent International AB (publ), Reg. No 556537-7263, are hereby invited to attend the Annual General Meeting (the "AGM") to be ...


13 Mar, 2019, 12:22 GMT BioInvent Expands U.S. Patent Protection for its F.I.R.S.T.™ Platform

BioInvent International AB (OMXS: BINV) announces today that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance,...


12 Mar, 2019, 10:36 GMT BioInvent Announces Publication of Review Article in Frontiers in Immunology on Resistance to Antibody Drugs

BioInvent International AB (OMXS: BINV), a company focusing on the discovery and development of novel and first-in-class immuno-modulatory antibodies ...


25 Feb, 2019, 07:31 GMT Notice of Extraordinary General Meeting in BioInvent International AB

The shareholders of BioInvent International AB (publ) (BINV) Reg. No. 556537-7263, are hereby invited to attend the Extraordinary General Meeting...


25 Feb, 2019, 07:24 GMT BioInvent Financial Statement January 1 - December 31, 2018

Fourth quarter 2018, October – December Net sales amounted to SEK 10.4 (13.5) million. Loss after tax SEK -32.7 (-33.3) million. Loss after tax per...


05 Feb, 2019, 07:54 GMT BioInvent CSO to Present F.I.R.S.T.™ Discovery Platform at SLAS2019

LUND, Sweden, Feb. 5, 2019 BioInvent International AB (OMXS: BINV) announces today that its Chief Scientific Officer, Björn Frendéus, will hold a...


30 Jan, 2019, 08:05 GMT BioInvent Receives FDA Orphan Designation for BI-1206 for Mantle Cell Lymphoma

BioInvent International AB (OMXS: BINV) announces today that the U.S. Food and Drug Administration (FDA) has granted the Company orphan designation...


20 Nov, 2018, 10:27 GMT BioInvent Signs Manufacturing Agreement With U.S. Cell Therapy Company

BioInvent International AB (OMXS: BINV) announced today that it has signed a manufacturing agreement with an undisclosed U.S. cell therapy company...


13 Nov, 2018, 17:31 GMT BioInvent Announces Publication of Data in Leading Cancer Journal Immunity

BioInvent International AB (OMXS: BINV) announced today the publication of data on the cellular and molecular mechanism-of-action of antibodies to...